common financing with most developmental biotechs. the company looks to have around 12 months of cash available based on current burn rate. i am anticipating a partner or licensing deal with interim p2 data, which could be in the next several months, although the better the treatment is working it could mean a longer timeframe. the real key to reading the financials are the lack of short and long term debt. that usually buries companies that cant get favorable terms when financing is needed.
'cmon fella's the original post was pointed, and it wasn't intended to illicit a reasoned answer. Who would, as a serious investor type, be ignorant enough to ask that question? One answer: Not anyone who could write a complete sentence. He did.